Recombinant Human VSD4-NaV1.7-NaVPas Protein (HEK293)，Flag & Strep

The research on the recombinant protein VSD4-NaV1.7-NaVPas is primarily rooted in the investigation of voltage-gated sodium channels, particularly NaV1.7, which plays a crucial role in the initiation and propagation of action potentials in neurons. NaV1.7 has garnered significant attention due to its involvement in pain signaling; mutations in the SCN9A gene, which encodes NaV1.7, are associated with various pain disorders, ranging from congenital insensitivity to pain to extreme pain sensitivity. Understanding the structure and function of this channel is essential for developing targeted analgesic therapies. The VSD4 region of NaV1.7, which is critical for voltage sensing, and its interaction with NaVPas (a peptide derived from the venom of the spider species, Loxosceles laeta) provide a unique insight into the modulation of sodium channels. This recombinant protein allows researchers to explore the intricate mechanisms of sodium channel gating and pharmacology, enhancing the prospective development of novel pain management strategies and channel blockers. By employing advanced genetic engineering techniques, the VSD4-NaV1.7-NaVPas recombinant construct enables the detailed study of channel behavior in response to voltage changes and pharmacological agents, contributing to a deeper understanding of pain mechanisms and the potential for innovative therapeutic approaches.